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Abstract 
Background: Antimicrobial resistance (AMR) is a public health crisis that is predicted to cause 10 million deaths per 
year by 2050. The environment has been implicated as a reservoir of AMR and is suggested to play a role in the dis-
semination of antibiotic resistance genes (ARGs). Currently, most research has focused on measuring concentrations 
of antibiotics and characterising the abundance and diversity of ARGs and antibiotic resistant bacteria (ARB) in the 
environment. To date, there has been limited empirical research on whether humans are exposed to this, and whether 
exposure can lead to measureable impacts on human health. Therefore, the objective of this work is to produce two 
linked systematic maps to investigate previous research on exposure and transmission of AMR to humans from the 
environment. The first map will investigate the available research relating to exposure and transmission of ARB/ARGs 
from the environment to humans on a global scale and the second will investigate the prevalence of ARB/ARGs in 
various environments in the UK. These two maps will be useful for policy makers and research funders to identify 
where there are significant gluts and gaps in the current research, and where more primary and synthesis research 
needs to be undertaken.
Methods: Separate search strategies will be developed for the two maps. Searches will be run in 13 databases, and 
grey literature will be sought from key websites and engagement with experts. Hits will be managed in EndNote and 
screened in two stages (title/abstract then full text) against predefined inclusion criteria. A minimum of 10% will be 
double screened with ongoing consistency checking. All included studies will have data extracted into a bespoke 
form designed and piloted for each map. Data to be extracted will include bibliographic details, study design, loca-
tion, exposure source, exposure route, health outcome (Map 1); and prevalence/percentage of ARB/ARG (Map 2). 
No validity appraisal will be undertaken. Results will be tabulated and presented narratively, together with graphics 
showing the types and areas of research that has been undertaken and heatmaps for key exposure-health outcomes 
(Map 1) and exposure-prevalence (Map 2).
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Background
Antibiotics are antimicrobials used to prevent and treat 
bacterial infections. Their efficacy is important as their 
use is critical in human and veterinary medicine, as well 
as in food production practices [1]. Presently, the effi-
cacy of antibiotics is being undermined by the ability of 
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bacteria to resist the actions of these drugs (antibiotic 
resistance). This results in treatment failure, prolonged 
morbidity and increased risk of mortality when treating 
infections caused by resistant pathogens [2]. The dev-
astating impact of such resistance has led to antibiotic 
resistance and antimicrobial resistance (AMR) more 
broadly, being placed on the UK Risk Register, along-
side other critical risks such as climate change, pan-
demic influenza and global terrorism [3, 4]. It has been 
predicted that by 2050 AMR will be the leading cause of 
death globally, accounting for 10 million deaths per year 
[2]. The term AMR includes resistance to agents with 
antimicrobial properties by microorganisms, such as bac-
terial, fungal, viral or parasitic organisms. It is frequently 
used interchangeably in the literature with the term anti-
biotic resistance. However, the focus of this study will be 
antibiotic resistant bacteria (ARB).
The occurrence of infections that are resistant to anti-
microbials is increasing globally [1, 5, 6]. Successful treat-
ment of resistant bacterial infections increasingly relies 
on more expensive “last-resort” antibiotics. Resistance 
has, however, already developed to such antibiotics, for 
example, colistin [7]. In addition, there are few novel anti-
microbials being discovered and coming to market, as the 
investment (in time and money) needed to develop these 
drugs is high and as small returns is promised in the life-
time of the patent [8]. In the last three decades, only two 
antibiotic classes, oxazolidinones and cyclic lipopeptides, 
have been brought to market [9]. Without the discovery 
of new antibiotics, and with the development of resist-
ance, it is possible that we will enter an era similar to that 
before the discovery of antibiotics, where routine medical 
procedures become far riskier as a result of our inability 
to prevent or treat infections which are currently simple 
to treat [10].
The 2014 O’Neill report, commissioned by the UK gov-
ernment, stated that the global number of deaths annu-
ally from AMR will increase from 700,000 in 2014 to 10 
million by 2050. This report also predicted that AMR 
will negatively impact the global economy, estimating 
a drop in the world’s GDP of 2.5% to 3% (up to 100 tril-
lion US dollars) between 2014 and 2050 as a consequence 
of AMR [2]. In the UK, the Chief Medical Officer stated 
that AMR infections already cost the NHS approximately 
£180 million every year [11].
There is a vast range of research that has been under-
taken investigating the impact of AMR from a clinical 
perspective [12–17]. However, the role of the environ-
ment in the dissemination of AMR is only recently being 
investigated. Human use of antibiotics has been impli-
cated in the rise of resistance, with our activities accel-
erating the development and dissemination of antibiotic 
resistance genes (ARGs) in and to the environment. In 
2017, the United Nations Environment Programme Fron-
tiers report highlighted AMR as the most critical emerg-
ing environmental pollution issue [18]. Although AMR is 
an ancient and natural phenomenon [19], the increased 
use of compounds with antimicrobial properties and 
their subsequent release into the environment through 
anthropogenic activities has increased the rate of the 
development of novel resistance and dissemination in 
such compartments [20]. For example, a large proportion 
(up to 90% [21]) of administered antibiotic is excreted in 
its biologically active form in both urine and faeces from 
treated patients and animals and this can be released 
into receiving environments such as soil and water [12] 
in concentrations that range from ng/L to µg/L [22]. 
Research has shown that these environmentally relevant 
concentrations of antibiotics are able to select for ARGs 
[23–27]. As a result of both naturally occurring ARGs, 
and selective pressure from antimicrobial compounds 
used by humans, research has found that ARGs are found 
ubiquitously throughout environmental compartments 
[20]. Furthermore, there is evidence that ARGs in envi-
ronmental bacteria have the potential to be taken up by 
human-associated bacteria and pathogenic bacteria via 
horizontal gene transfer [28, 29], and that people exposed 
to AMR in the environment are at greater risk of being 
faecal carriers of AMR compared to people with less 
exposure [30].
This topic area has been previously mapped to the 
Driver-Pressure-State-Exposure-Effect-Action (DPSEEA) 
Framework [31]. The basic DPSEEA Framework can be 
seen in Fig. 1.
For environmental AMR research: “Driver” may refer 
to increasing number of resistant infection; “Pressure” 
may refer to inappropriate disposal of antimicrobials or 
other co-selecting agents into the environment; “State” 
may refer to the concentration levels of antimicrobials 
in the environment or abundance of resistant organisms 
or genes; “Exposure” may refer to direct contact with 
the environment resulting in inhalation or consumption 
of resistant organisms or genes; “Effect” may refer to the 
human health outcome of this exposure and “Action” may 
refer to any action taken at any stage of this framework to 
mitigate the human health outcome.
The majority of the research undertaken investigat-
ing AMR in the environment has focused on identifying 
Drivers Pressures State Exposure Effect
Action
Fig. 1 DPSEEA Framework adapted from Morris et al. [32]
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and quantifying the discharge of various chemical and 
microbial pollutants (Pressure and State), including the 
concentrations of antimicrobials [33–35], ARB [36–38] 
and ARGs [39–41] in the environment. However, there 
is limited data on the fate of these pollutants (Expo-
sure and Effect). The question of whether AMR levels in 
the environment are high enough to pose an exposure 
risk to humans, and if environmental resistant bacteria 
are transmitted to humans and threaten public health 
remains and is a key consideration for policy-makers 
around the world.
There has been relatively little evidence synthesis work 
on environmental AMR. One recent systematic review 
investigated what was the most effective control measure 
in preventing the dissemination of AMR in the environ-
ment [42]. This work, however, did not investigate the 
potential exposure and transmission of environmental 
AMR to humans. To the best of the authors’ knowledge, 
there has not been any evidence synthesis work investi-
gating this.
The aim of this article is to provide a systematic map 
protocol. Here we are following ROSES for systematic 
map protocol reporting standards (provided as an Addi-
tional file 1) and CEE guidance for methods.
Stakeholder engagement
Initial revising of the scope of the question for the two 
maps was undertaken through a meeting with a member 
from the Environment Agency.
Subsequently, a number of stakeholders were asked to 
make comments on the inclusion and exclusion crite-
ria, search terms and sources of grey literature via email. 
These stakeholders were from: Animal and Plant Health 
Agency; AstraZeneca; Centre for Environment, Fisher-
ies and Aquaculture Science; Department for Environ-
mental, Food & Rural Affairs; Environment Agency; Food 
Standards Agency; Joint Nature Conservation Commit-
tee; Public Health England; Severn Trent Water and Vet-
erinary Medicines Directorate.
A further meeting was held to further discuss sources 
of grey literature searching, outputs of the maps that 
stakeholders would find most useful and potential means 
of dissemination of the outputs through stakeholder 
organisations using directed questions. This was attended 
by members from organisations mentioned above, in 
addition to: Department of Agriculture, Environment 
and Rural Affairs; GlaxoSmithKline; Public Health Eng-
land; Royal Devon & Exeter Hospital Trust; Severn Trent 
Water; Welsh Government and Wessex Water.
Finally, stakeholders will be consulted to discuss pre-
liminary findings, to ensure that outputs are meaningful 
to specific organisations and that key gaps and gluts of 
evidence are prioritised for the maps. Outputs will not 
exclusively be those which are suggested by stakehold-
ers and suggestions from stakeholders will be discussed 
by the team to ensure non-biased outputs whilst encom-
passing stakeholder suggestions and priorities. These 
discussions were originally planned to be undertaken as 
another formal meeting. As a result of the global pan-
demic this will now take place via informal means such as 
email, virtual meetings and/or telephone interviews.
Objective of review
The aim is to conduct systematic mapping exercise in 
order to provide data on current evidence and identify 
research gluts and gaps relating to AMR in the environ-
ment and whether this can affect human health.
Primary research question: What research evidence is 
there that humans are exposed to and affected by AMR 
in the environment?
This will be broken down into two evidence maps:
Map  1: What research evidence is there about 
ARB exposure and transmission to humans from the 
environment?
This will include studies that investigate either meas-
ureable health outcomes (e.g. colonisation, infection or 
mortality) or an estimated exposure risk in humans via 
direct contact such as inhalation or consumption from 
antibiotic resistant bacteria from environmental sources 
(e.g. water or soil sources).
Map 2: What research evidence is there measuring the 
prevalence of ARB in the environment in the UK? This 
will be UK based as the funding’s remit is for UK policy 
based research. This will help to elucidate which environ-
ments have been extensively researched and which are 
currently under researched.
This will include studies that investigate the prevalence, 
percentage or abundance of resistant bacteria in environ-
ments such as various water environments and soil envi-
ronments for example.
Methods
Searching for articles
Medline via OvidSP has been used to develop and refine 
the bibliographic database searches for both maps by the 
information specialist (AB) through a process of scop-
ing, checking against a list of known includable papers 
and with the project team. Both free text terms and con-
trolled vocabulary terms were used when available and 
relevant. This search will be translated across the follow-
ing databases:
Medline (1946–present), CAB Abstracts (1973–pre-
sent), Global Health (via OvidSP, 1973–present), BIOSIS 
Citation Index (1969–present), Web of Science Core Col-
lection (via Web of Science, 1900–present), GreenFILE, 
Environment Complete (via EBSCOhost, 1888–present), 
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SCOPUS (1788–present), Epistemonikos, ProQuest Dis-
sertations and Theses Global (via ProQuest, 1637–pre-
sent), Explore (via the British Library), and AGRIS (via 
FAO). Please note that these databases will be limited by 
a search date (details can be found below).
All the results for both maps will be downloaded into 
Endnote X8 where duplicates will be removed. Sup-
plementary search methods will be used for both maps 
to attempt to capture additional relevant information 
including forwards and backwards citation searching of 
included articles, hand searching of relevant journals and 
searching within organisational websites.
The Medline search string for both maps can be found 
in an Additional file 2 (Medline search strategy).
For Map 2:
To focus searches to geographically relevant studies, 
a modified version of the MEDLINE Ovid UK search 
filter [43] will be used for all the bibliographic database 
searches in Map 2.
Key author searches on both Web of Science Core Col-
lection and SCOPUS will be run for Gaze, W. Welling-
ton, E. and Amos, GC. These authors were chosen based 
on expert advice as key people working and publishing 
in this field in the UK. These results will be added to the 
other database search results.
Google scholar searches will also be carried out using 
a simplified search string with the first 1000 hits being 
downloaded. We will search google scholar using the 
Publish or Perish software using the following two 
strings: “Antimicrobial resistance and UK” and “Anti-
microbial resistance and United Kingdom” both just in 
the title. These results will be added to the other search 
results.
The following websites will be searched:
Cefas (Centre for Environment, Fisheries and Aquacul-
ture Science)
EA (Environment Agency)
SEPA (Scottish Environmental Protection Agency)
Defra (Department of Environment, Food and Rural 
Affairs)
APHA (Animal and Plant Health Agency)
VMD (Veterinary Medicines Directorate)
PHE (Public Health England)
CARS (Control of Antimicrobial Resistance Scotland)
HPS (Health Protection Scotland)
Welsh government
Limits
For both maps, only studies published in English will be 
considered due to limited resources and as this is rele-
vant to UK policy scenarios for Map 2. Map 1 will be date 
limited to evidence published from 2009 and Map 2 date 
limited to 2005.
Estimating the comprehensiveness of the search
The comprehensiveness of both of the maps have 
been tested by using key papers that were known to be 
included after full text screening to validate that the 
searches were identifying these. For Map  1, 11 publica-
tions were used and for Map 2, 8 publications were used. 
A list of these references for both maps can be found as 
an Additional file 3 (Key papers). The final searches were 
able to identify all key papers for both questions.
Search update
The searches will not be updated prior to publication as 
this is a short term project. It is expected that the results 
of this systematic mapping exercise will be available 
within a year of the search date.
Article screening and study eligibility criteria
Screening strategy
Studies retrieved from the searches will be imported into 
EndNote, duplicates will be removed and articles will be 
screened in two stages. An initial screening of 100 arti-
cles will be undertaken at title and abstract stage and 
discussion of all will occur between reviewers to ensure 
consistency. Titles and abstracts will be screened against 
the inclusion and exclusion criteria by one reviewer (as 
a result of resource constraints), with at least 10% of 
results being screened by a second reviewer to ensure 
consistency. Kappa coefficient will be used to evaluate 
consistency between the two reviewers. The kappa coef-
ficient will be used as a guide and if the score is equal to 
or below 0.6, this will prompt discussion points, refining 
of the eligibility criteria and a further evaluation of 100 
articles will be undertaken and discussions will occur. In 
addition, all discrepancies will be discussed by the two 
reviewers and the wider review team will be consulted if 
necessary. At the second stage, full texts identified in the 
first screening will be assessed for their eligibility with 
one reviewer screening and extracting meta-data from all 
articles (as a result of resource constraints) and a mini-
mum of 10% being screened and extracted by a second 
reviewer. Reviewers that have authored papers which are 
found during the searching process will not review these 
publications to avoid biases towards these publications. 
These papers will be screened at both abstract and title 
screening and full text screening by an impartial reviewer.
A list of studies that are excluded at full text screening 
will be made available with reasons for exclusion.
Eligibility criteria
Map 1
Details of the eligibility criteria and justifications for 
these are presented in Table 1. The question is expressed 
in a PEO format (Population, Exposure, Outcome) with 
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the exposure sources and routes both considered impor-
tant for this question.
Map 2
Details of the eligibility criteria justifications for these are 
presented in Table 2. The question is expressed in a PEO 
format (Population, Exposure, Outcome) with the expo-
sure sources and routes both considered important for 
this question.
Relevant types of study
Studies will be commercially published work and grey 
literature. For Map  1, these studies will include system-
atic reviews, experimental studies (randomised exposure 
trials), observational studies (prospective/retrospective 
cohort studies, cross-sectional studies, case studies and 
case series) and modelling studies (for example quanti-
tative microbial risk assessments). For Map  2, relevant 
study types will include systematic reviews and environ-
mental surveillance studies.
Location
Whilst Map 1 will not include geographic limitations on 
study location, Map  2 will be restricted to only include 
studies where data is available from locations in the 
United Kingdom. There are expected to be many more 
eligible studies for Map 2 than for Map 1, and due to lim-
ited resources, data pertinent to the UK has been priori-
tised so that this map will be of most use to UK based 
policy makers and stakeholders.
Date range
For Map 1, literature published in the past 10 years (from 
2009) will be included. Older studies will be excluded, but 
eligible research prior to this date is unlikely. For Map 2, 
searching will be extended to include studies published 
between 2005 and the present, as this is when interest in 
the topic of AMR in the environment started to increase. 
These dates have been selected based on advice from 
experts in the field.
Study validity assessment
No formal validity appraisal of included studies will be 
performed. However, study designs of included studies 
will be extracted for the maps.
Data coding strategy
For both of the maps we will extract the following meta-
data: bibliographic information; study location; study 
type; exposure source (main category—water, food, air, 
sediment, soil, animal faeces); exposure source (sub-cat-
egories. For example—Water: coastal, river, lake, ground-
water, wastewater treatment plant influent, wastewater 
treatment plant effluent, drinking, crop irrigation etc.); 
whether there was a comparator and outcome.
For Map 1, information on population types and expo-
sure route will also be extracted.
For Map 2, information about the experimental meth-
odology used will also be extracted.
Study mapping and presentation
We will follow ROSES guidance for reporting on the 
systematic maps [44]. As well as the narrative synthesis 
of the systematic maps, data collected from the eligi-
ble studies will be recorded in an Excel spreadsheet and 
made available as an additional file. Both maps will be 
presented using the EviAtlas tool and will be uploaded 
online [45]. We plan to display: the location of the stud-
ies; heatmaps showing different exposure sources or 
routes by different outcome measures and details of the 
impact to relevant populations.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1375 0-020-00197 -6.
Additional file 1. ROSES for Systematic Map Protocols checklist. 
Additional file 2. Medline search strategy. 
Additional file 3. Key papers for validating the search strategy.
Table 2 Eligibility criteria for Map 2
ARB antibiotic resistant bacteria, ARG antibiotic resistance gene, AMR antimicrobial resistance
Inclusion Exclusion Justification
Population Bacteria Fungi, parasites, viruses ARBs are a priority interest for relevant stakeholders. Resource 
constraints mean other types of AMR organisms will not be 
included
Exposure sources As in Table 1 As in Table 1 As in Table 1
Exposure routes Exposure to AMR organisms
Outcomes Prevalence/percentage of ARB
Prevalence/percentage of ARGs
Presence of ARB/ARGs 
with no quantification
Page 7 of 8Stanton et al. Environ Evid            (2020) 9:12  
Acknowledgements
We would like to thank stakeholders who have engaged with us for their valu-
able contribution to defining the scope of this work.
Authors’ contributions
AL, WG, RG conceived of the project. IS, AL, WG and RG developed the inclu-
sion/exclusion criteria. AB developed the search terms and strings. AB wrote 
the draft manuscript sections related to the searching. IS wrote the draft of all 
other sections. All authors read and revised the drafted manuscript. All authors 
read and approved the final manuscript.
Funding
This work is funded by the Natural Environment Research Council (NERC) 
Environmental Evidence for the Future (EEF) Grant (NE/S015965/1). AL is sup-
ported by a NERC Industrial Innovation Fellowship Grant (NE/R013748/1).
Availability of data and materials
Not applicable
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing financial interests.
Author details
1 European Centre for Environment and Human Health, College of Medicine 
and Health, Penryn Campus, University of Exeter, Penryn TR10 9FE, UK. 2 Col-
lege of Medicine and Health, St Luke’s Campus, University of Exeter, Exeter EX1 
1TX, UK. 3 European Centre for Environment and Human Health, College 
of Medicine and Health, Knowledge Spa, University of Exeter, Truro TR1 3HD, 
UK. 
Received: 1 April 2020   Accepted: 25 May 2020
References
 1. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob 
Chemother. 2009;64:29–36.
 2. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and 
wealth of nations. Rev Antimicrob Resist. 2014;20:1–16. https ://amr-revie 
w.org/sites /defau lt/files /AMR%20Rev iew%20Pap er%20-%20Tac kling 
%20a%20cri sis%20for %20the %20hea lth%20and %20wea lth%20of%20nat 
ions_1.pdf.
 3. Cabinet Office. National Risk Register of Civil Emergencies 2015 edition. 
2015.
 4. Cabinet Office. National Risk Register of Civil Emergencies 2017 edition. 
2017.
 5. Finley RL, Collignon P, Larsson DG, McEwen SA, Li XZ, Gaze WH, et al. The 
scourge of antibiotic resistance: the important role of the environment. 
Clin Infect Dis. 2013;57(5):704–10.
 6. Wellington EM, Boxall AB, Cross P, Feil EJ, Gaze WH, Hawkey PM, et al. The 
role of the natural environment in the emergence of antibiotic resistance 
in gram-negative bacteria. Lancet Infect Dis. 2013;13(2):155–65.
 7. Nhu NTK, Riordan DW, Nhu TDH, Thanh DP, Thwaites G, Lan NPH, et al. 
The induction and identification of novel Colistin resistance mutations in 
Acinetobacter baumannii and their implications. Sci Rep. 2016;6:1–8.
 8. O’Neill J. Securing new drugs for future generations: the pipeline of 
antibiotics. Rev Antimicrob Resist. 2015;1–41.
 9. Gupta SK, Nayak RP. Dry antibiotic pipeline: regulatory bottlenecks and 
regulatory reforms. J Pharmacol Pharmacother. 2014;5(1):4–7.
 10. WHO. Antimicrobial resistance. Bull World Health Organ. 
2014;61(3):383–94.
 11. O’Dowd A. Death certificates should record antimicrobial resistance as 
cause of deaths, says CMO. BMJ. 2018;362:k3832.
 12. Singer AC, Shaw H, Rhodes V, Hart A. Review of antimicrobial resistance 
in the environment and its relevance to environmental regulators. Front 
Microbiol. 2016;7:1728.
 13. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. 
Worldwide H. pylori antibiotic resistance: a systematic review. J Gastroin-
testin Liver Dis. 2010;19(4):409–14.
 14. Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic 
review and meta-analysis of the effects of antibiotic consumption on 
antibiotic resistance. BMC Infect Dis. 2014;14:13.
 15. Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald 
LK, et al. Surveillance of antimicrobial use and antimicrobial resistance 
in United States hospitals: project ICARE phase 2. Project Intensive Care 
Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis. 
1999;29(2):245–52.
 16. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of 
antimicrobial resistance in Pseudomonas aeruginosa isolates obtained 
from intensive care unit patients from 1993 to 2002. Antimicrob Agents 
Chemother. 2004;48(12):4606–10.
 17. Kumari M, Batra P, Malhotra R, Mathur P. A 5-year surveillance on anti-
microbial resistance of Acinetobacter isolates at a level-I trauma centre 
of India. J Lab Physicians. 2019;11(1):34–8.
 18. Gaze WH, Depledge M. Antimicrobial resistance: investigating the 
environmental dimension. Frontiers 2017: Emerging Issues of Environ-
mental Concern. United Nations Environment Programme. 2017:12–22. 
https ://wedoc s.unep.org/handl e/20.500.11822 /22263 ?show=full.
 19. D’Costa VM, King CE, Kalan L, Morar M, Sung WWL, Schwarz C, et al. 
Antibiotic resistance is ancient. Nature. 2011;477(7365):457–61.
 20. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey 
A, et al. Understanding the mechanisms and drivers of antimicrobial 
resistance. Lancet. 2016;387(10014):176–87.
 21. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of 
antibacterial agents. Infect Dis Clin N Am. 2009;23(4):791–815.
 22. Andersson DI, Hughes D. Evolution of antibiotic resistance at non-
lethal drug concentrations. Drug Resist Update. 2012;15(3):162–72.
 23. Murray AK, Zhang L, Yin X, Zhang T, Buckling A, Snape J, et al. Novel 
insights into selection for antibiotic resistance in complex microbial 
communities. mBio. 2018;9(4):e00969-18.
 24. Lundstrom SV, Ostman M, Bengtsson-Palme J, Rutgersson C, Thoudal 
M, Sircar T, et al. Minimal selective concentrations of tetracycline in 
complex aquatic bacterial biofilms. Sci Total Environ. 2016;553:587–95.
 25. Kraupner N, Ebmeyer S, Bengtsson-Palme J, Fick J, Kristiansson E, 
Flach CF, et al. Selective concentration for ciprofloxacin resistance in 
Escherichia coli grown in complex aquatic bacterial biofilms. Environ 
Int. 2018;116:255–68.
 26. Gullberg E, Albrecht LM, Karlsson C, Sandegren L, Andersson DI. Selec-
tion of a multidrug resistance plasmid by sublethal levels of antibiotics 
and heavy metals. mBio. 2014;5(5):e01918-14.
 27. Gullberg E, Cao S, Berg OG, Ilback C, Sandegren L, Hughes D, et al. 
Selection of resistant bacteria at very low antibiotic concentrations. 
PLoS Pathog. 2011;7(7):e1002158.
 28. Canton R, Jose MGA, Galan JC. CTX-M enzymes: origin and diffusion. 
Front Microbiol. 2012;3:110.
 29. Ashbolt NJ, Amezquita A, Backhaus T, Borriello P, Brandt KK, Collignon P, 
et al. Human Health Risk Assessment (HHRA) for environmental devel-
opment and transfer of antibiotic resistance. Environ Health Perspect. 
2013;121(9):993–1001.
 30. Leonard AFC, Zhang L, Balfour AJ, Garside R, Hawkey PM, Murray AK, 
et al. Exposure to and colonisation by antibiotic-resistant E. coli in UK 
coastal water users: environmental surveillance, exposure assess-
ment, and epidemiological study (Beach Bum Survey). Environ Int. 
2018;114:326–33.
 31. Leonard AFC. Are bacteria in the coastal zone a threat to human health? 
[Thesis]. University of Exeter; 2016.
 32. Morris GP, Beck SA, Hanlon P, Robertson R. Getting strategic about 
the environment and health. Public Health. 2006;120(10):889–903 
(discussion-7).
 33. Hirsch R, Ternes TA, Haberer K, Mehlich A, Ballwanz F, Kratz K. Determina-
tion of antibiotics in different water compartments via liquid chroma-
tography–electrospray tandem mass spectrometry. J Chromatogr A. 
1998;815(2):213–23.
Page 8 of 8Stanton et al. Environ Evid            (2020) 9:12 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 34. Kostich MS, Batt AL, Lazorchak JM. Concentrations of prioritized pharma-
ceuticals in effluents from 50 large wastewater treatment plants in the US 
and implications for risk estimation. Environ Pollut. 2014;184:354–9.
 35. Boxall AB, Blackwell P, Cavallo R, Kay P, Tolls J. The sorption and 
transport of a sulphonamide antibiotic in soil systems. Toxicol Lett. 
2002;131(1–2):19–28.
 36. Armstrong JL, Shigeno DS, Calomiris JJ, Seidler RJ. Antibiotic-resistant 
bacteria in drinking water. Appl Environ Microbiol. 1981;42(2):277–83.
 37. Schwartz T, Kohnen W, Jansen B, Obst U. Detection of antibiotic-resistant 
bacteria and their resistance genes in wastewater, surface water, and 
drinking water biofilms. FEMS Microbiol Ecol. 2003;43(3):325–35.
 38. Boehme S, Werner G, Klare I, Reissbrodt R, Witte W. Occurrence of 
antibiotic-resistant enterobacteria in agricultural foodstuffs. Mol Nutr 
Food Res. 2004;48(7):522–31.
 39. Chen Q, An X, Li H, Su J, Ma Y, Zhu Y. Long-term field application of sew-
age sludge increases the abundance of antibiotic resistance genes in soil. 
Environ Int. 2016;92–93:1–10.
 40. Marti R, Scott A, Tien Y, Murray R, Sabourin L, Zhang Y, et al. Impact of 
manure fertilization on the abundance of antibiotic-resistant bacteria 
and frequency of detection of antibiotic resistance genes in soil and on 
vegetables at harvest. Appl Environ Microbiol. 2013;79(18):5701–9.
 41. Zhang XX, Zhang T, Fang HH. Antibiotic resistance genes in water envi-
ronment. Appl Microbiol Biotechnol. 2009;82(3):397–414.
 42. Goulas A, Belhadi D, Descamps A, Andremont A, Benoit P, Courtois S, et al. 
How effective are strategies to control the dissemination of antibiotic 
resistance in the environment? A systematic review. Environ Evid. 
2020;9(4):1–32.
 43. Ayiku L, Levay P, Hudson T, Craven J, Barrett E, Finnegan A, et al. The med-
line UK filter: development and validation of a geographic search filter 
to retrieve research about the UK from OVID medline. Health Info Libr J. 
2017;34(3):200–16.
 44. Haddaway NR, Macura B, Whaley P, Pullin AS. ROSES RepOrting standards 
for Systematic Evidence Syntheses: pro forma, flow-diagram and descrip-
tive summary of the plan and conduct of environmental systematic 
reviews and systematic maps. Environ Evid. 2018;7:7.
 45. Haddaway NR, Feierman A, Grainger MJ, Gray CT, Tanriver-Ayder E, 
Dhaubanjar S, et al. EviAtlas: a tool for visualising evidence synthesis 
databases. Environ Evid. 2019;8(1):22.
 46. Madden JR, Hall A, Whiteside MA. Why do many pheasants released in 
the UK die, and how can we best reduce their natural mortality? Eur J 
Wildlife Res. 2018;64(4):40.
 47. Nuesch-Inderbinen M, Treier A, Zurfluh K, Stephan R. Raw meat-based 
diets for companion animals: a potential source of transmission of 
pathogenic and antimicrobial-resistant Enterobacteriaceae. R Soc Open 
Sci. 2019;6(10):191170.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
